Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Research & Development (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Research & Development for 11 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 57.91% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.8 million through Dec 2025, down 12.39% year-over-year, with the annual reading at $11.8 million for FY2025, 12.39% down from the prior year.
  • Research & Development for Q4 2025 was $2.1 million at Marker Therapeutics, down from $2.3 million in the prior quarter.
  • The five-year high for Research & Development was $8.0 million in Q4 2021, with the low at $2.0 million in Q3 2023.
  • Average Research & Development over 5 years is $4.0 million, with a median of $3.3 million recorded in 2023.
  • The sharpest move saw Research & Development crashed 72.78% in 2022, then soared 94.33% in 2024.
  • Over 5 years, Research & Development stood at $8.0 million in 2021, then plummeted by 72.78% to $2.2 million in 2022, then grew by 19.93% to $2.6 million in 2023, then skyrocketed by 94.33% to $5.1 million in 2024, then plummeted by 57.91% to $2.1 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.1 million, $2.3 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.